MOTS-c Dosage Chart: 1mg Daily, 5-On/2-Off Protocol

MOTS-c is a 16-amino-acid mitochondrial-derived peptide; published research documents it activating AMPK and enhancing glucose metabolism, insulin sensitivity, and fatty acid oxidation (Lee et al., 2015). It's frequently described as an "exercise mimetic" — though it complements exercise rather than replacing it.

Research-context information only. MOTS-c is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

No MOTS-c formulation is FDA-approved. All protocols below are derived from published research and community experience. This is not medical advice.

Quick Reference: Standard Protocol

For a comparison of MOTS-c vs SS-31 (Elamipretide), see our SS-31 vs MOTS-c comparison.

Cycling Details

The standard cycle is 1 mg daily (5 on / 2 off) for 8 weeks, then 8 weeks off. The rationale is AMPK-mTOR balance — chronic AMPK activation can suppress mTOR-mediated protein synthesis, so cycling allows the body to alternate between metabolic optimization (AMPK-dominant) and growth/repair (mTOR-dominant) phases.

Morning dosing aligns with natural metabolic rhythms and complements exercise — Lai et al. (2021) showed that exercise itself induces endogenous MOTS-c expression, and intermittent dosing (3x/week) was sufficient to improve physical capacity in aged mice (Lai et al., 2021).

Enhanced Metabolic Protocol (Community)

For individuals targeting metabolic improvement or body composition, community protocols use higher doses based on the original animal research:

5 mg is derived from animal studies using 5 mg/kg IP (which does not translate linearly to humans). Community protocols describe combining it with structured exercise and tracking fasting insulin, HOMA-IR, lipid panel, and body composition.

Routes of Administration

Subcutaneous injection is the standard route — abdomen, thigh, or love handles. Protocols describe a 29-31 gauge insulin syringe. Volume is typically 0.2 mL for the standard 1 mg dose.

No oral route — MOTS-c is a peptide that would be destroyed by digestive enzymes.

Reconstitution Quick Reference

Math: 10 mg / 2 mL = 5 mg/mL = 5,000 mcg/mL. For 1 mg: 1 / 5 = 0.2 mL = 20 units.

Swirl gently — do not shake. Refrigerate after mixing, use within 28 days. Store unreconstituted vials at -20 C. For step-by-step instructions, see the full MOTS-c Reconstitution Guide.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

MOTS-c was first identified by Changhan Lee and colleagues in 2015 as a mitochondrial-encoded signaling peptide (Lee et al., 2015). The key findings driving current protocols:

AMPK activation mechanism: MOTS-c targets the methionine-folate cycle, raising cellular AICAR concentrations that activate AMPK. Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus to regulate adaptive gene expression (Kim et al., 2018).

Late-life efficacy: MOTS-c treatment initiated at the mouse equivalent of ~70 human years improved physical capacity and healthspan with intermittent dosing (3x/week) (Lai et al., 2021).

Exercise mimetic context: MOTS-c activates overlapping pathways with exercise (AMPK, glucose uptake, fat oxidation) but does not replicate cardiovascular adaptation, bone loading, or neuromuscular development. It's best understood as a metabolic supplement to exercise, not a replacement.

Stacking Protocols

MOTS-c and SS-31 work through completely different mechanisms — MOTS-c signals via AMPK while SS-31 physically stabilizes cardiolipin. See our SS-31 vs MOTS-c comparison for a detailed breakdown.

Side Effects & Safety

• Injection site reactions — redness, mild pain, or swelling (more common with larger volumes)
• Transient hypoglycemia-like symptoms — light-headedness or hunger if dosed fasted, reflecting glucose-lowering activity
• Mild GI discomfort — nausea or stomach upset, typically first few days only
• Mild flushing or warmth — occasional, transient
• AMPK-mTOR trade-off — chronic AMPK activation may suppress muscle protein synthesis (rationale for cycling)
• Drug interaction: metformin — both activate AMPK; additive glucose-lowering possible, and community protocols describe tracking blood glucose in this scenario.
• Populations excluded from published trials: Type 1 diabetes subjects were excluded from MOTS-c research protocols (unpredictable glucose variability); no safety data exist for pregnant or breastfeeding subjects. Community sources describe heightened monitoring in both scenarios.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once MOTS-c is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 1 mL BAC water (10 mg/mL) — less BAC water for a lower total volume, so smaller draws and less fridge space.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.